Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](CTI BioPharma)"
Count: 63
Selected: 0
| NCT ID | Title |
|---|
| NCT05657613 | Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects | ||
| NCT05552183 | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib | ||
| NCT04884191 | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib | ||
| NCT04404361 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | ||
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ||
| NCT02823171 | To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects | ||
| NCT02808455 | Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects | ||
| NCT02807207 | To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects | ||
| NCT02807116 | Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects | ||
| NCT02807077 | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects | ||
| NCT02807051 | To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects | ||
| NCT02803762 | Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib | ||
| NCT02800889 | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | ||
| NCT02765724 | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects | ||
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | ||
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | ||
| NCT01638442 | Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects | ||
| NCT01632436 | Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment | ||
| NCT01321541 | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant | ||
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | ||
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | ||
| NCT00551733 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | ||
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | ||
| NCT00291837 | CT-2106 for the Second Line Treatment of Ovarian Cancer | ||
| NCT00291785 | Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer | ||
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. | ||
| NCT00268853 | A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin | ||
| NCT00106600 | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | ||
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | ||
| NCT00069901 | Phase II CT-2103/Carboplatin in Ovarian Cancer | ||
| NCT00060684 | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | ||
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | ||
| NCT00054210 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | ||
| NCT00054197 | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | ||
| NCT00054184 | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer | ||
| NCT00020969 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | ||
| NCT00017433 | Arsenic Trioxide in Treating Patients With Multiple Myeloma | ||
| NCT00017069 | Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma | ||
| NCT00004026 | CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy | ||
| NCT02584777 | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis | ||
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | ||
| NCT02469415 | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | ||
| NCT02452346 | Study of Clinical Efficacy and Safety of Tosedostat in MDS | ||
| NCT02410551 | Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | ||
| NCT02323607 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | ||
| NCT02277093 | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | ||
| NCT01491841 | IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma | ||
| NCT01227408 | Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | ||
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | ||
| NCT00660218 | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer |
